吉西他滨联合顺铂治疗晚期乳腺癌临床疗效观察

目的比较晚期乳腺癌采用吉西他滨加顺铂与长春瑞滨加顺铂化疗的疗效、生存期和毒副作用。方法64例晚期乳腺癌患者随机分为两组,A组32例,采用吉西他滨加顺铂;B组32例,采用长春瑞滨加顺铂,进行疗效分析和毒副作用比较。结果A组CR 1例,PR 18例,总有效率59.4%,1年生存率53.1%,中位生存期8.9个月,肿瘤进展时间2～16个月,Karnofsky评分平均提高15分;B组CR 1例,PR 14例,总有效率46.9%,1年生存率34.4%,中位生存期7.7个月,肿瘤进展时间2～14个月,Karnofsky评分平均提高10分。两组间总有效率、1年生存率差异无显著性(P>0.05)。最常见的毒副反应为骨髓抑制,两组差异无显著性(P>0.05)。结论吉西他滨加顺铂治疗晚期乳腺癌疗效明显,耐受性好。

Observation of efficacy of combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced breast cancer

Objective To compare the efficacy and toxicity between combination of gemcitabine and cisplatin(group A) and combination of navelbine and cisplatin(group B)in treatment of advanced breast cancer.Method Sixty-four patients with advanced breast cancer were enrolled into the study and divided into 2 groups:thirty-two patients in group A and thirty-two patients in group B.Results In group A,objec- tive response rate was 59.4%,the 1-year survival rate was 53.1% and the median survival duration was 8.9 months.In group B,objective response rate was 46.9%,the 1-year survival rate was 34.4% and the medi- an survival duration was 7.7 months.There was no remarkable difference in the overall response rate and 1- year survival rates between the two groups.Myelosuppression was the major dose-limiting toxicity.Conclu- sion The combination of gemcitabine and cisplatin is effective and safe in treatment of advanced breast